Lee Swem is currently the Chief Development Officer at Kanvas Biosciences, where he leads the development of microbial LBP products. The company’s clinical development programs are focused on microbiome-based treatments for severe unmet needs in humans.
Lee Swem was previously Chief Scientific Officer at Federation Bio, which he helped launch in January 2019 with founders from Stanford University and Venrock. He successfully led the company through a Seed ($10M) and Series A ($50M) financing prior to the assets being acquired by Kanvas Biosciences. Prior to this position, Lee served as Senior Vice President and Chief Scientific Officer, Vice President of Research, and Director of the Therapeutic Antibody Program at Achaogen from 2014 to 2018. Before joining Achaogen, Lee was a Scientist in the Department of Infectious Disease at Genentech. During his tenure at Genentech, Lee started and led the anti-influenza A program, the anti-influenza B program, and began a small molecule anti-bacterial program.
Lee received his Ph.D. from Indiana University. Lee has authored several INDs and over 25 patents and publications.